Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atidarsagene autotemcel - Orchard Therapeutics

Drug Profile

Atidarsagene autotemcel - Orchard Therapeutics

Alternative Names: ARSA gene therapy - GSK/Fondazione Telethon/Ospedale San Raffaele; ARSA transduced autologous CD34+ stem cells - GSK/Fondazione Telethon/Ospedale San Raffaele; Arylsulfatase A gene therapy -GSK/Fondazione Telethon/Ospedale San Raffaele; Ex vivo stem cell gene therapy - GSK/Fondazione Telethon/Ospedale San Raffaele; GSK 2696274; Lenmeldy; Libmeldy; OTL-200

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Developer Orchard Therapeutics; The San Raffaele Telethon Institute for Gene Therapy (JV)
  • Class Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Arylsulfatase replacements; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Metachromatic leukodystrophy

Most Recent Events

  • 20 Mar 2024 US FDA plans to launch Lenmeldy™ for the treatment of Metachromatic leukodystrophy (In children) in USA
  • 19 Mar 2024 Registered for Metachromatic leukodystrophy (In children) in USA (IV)
  • 19 Mar 2024 Interim efficacy and adverse events data from a clinical trial in Metachromatic leukodystrophy released by Orchard Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top